UK practitioners cannot legally advertise botulinum toxin or any other prescription-only medicine to the public. This applies to websites, social media, email lists, and paid adverts. The Advertising Standards Authority and the MHRA have made the rules explicit, and enforcement is active. Here is what the prohibition covers, where practitioners get caught, and what compliant marketing looks like.
Why Injectable Advertising Is a Specialist Compliance Area
Botulinum toxin, sold under brand names including Botox, Vistabel, and Dysport, is a prescription-only medicine (POM) in the UK. So is hyaluronidase, used to dissolve filler. The classification is pharmaceutical, not cosmetic. That means the same rules governing the advertising of any POM apply to your clinic's social posts, website copy, and promotional emails.
The MHRA is the UK regulator for medicines advertising. The Advertising Standards Authority administers the CAP (Committee of Advertising Practice) code, the enforceable standard for non-broadcast advertising in the UK. Both bodies agree: advertising a POM to the general public breaches law and code. The prohibition is not a guideline. It is a requirement.
For aesthetic practitioners operating within the UK regulation framework, this is one of the clearest lines in the compliance landscape. It is also one of the most consistently crossed.
What the Law Says: Prescription Medicines and Public Advertising
The Human Medicines Regulations 2012, Regulation 285, prohibits advertising a POM to members of the public. Advertising is defined broadly: it covers anything designed to promote the prescription, supply, sale, or use of a medicinal product.
The MHRA's position is unambiguous: prescription medicines should only be promoted on platforms explicitly directed at healthcare professionals and clearly marked as such. General social media (Instagram, Facebook, TikTok, X) is public-facing by definition. Posting about your toxin or Botox service on a publicly accessible account is advertising a POM to the public, regardless of your intended audience.
This catches practitioners who believe that marketing their service is different from marketing the medicine. In regulatory terms, it is not. If your post makes clear you offer botulinum toxin treatments, it is promoting the use of that POM.
What the ASA and CAP Code Prohibit in Practice
The ASA's guidance on botulinum toxin products is specific. Under CAP rule 12.12, prescription medicines cannot be advertised to the public. The ASA considers almost any reference to botulinum toxin or its brand names in publicly accessible advertising to be a clear breach.
Prohibited practices include:
- Naming the product. Referencing Botox, Vistabel, Dysport, or any other botulinum toxin brand in public marketing.
- Using indirect synonyms. Terms such as "wrinkle-relaxing injections," "anti-wrinkle treatments," and "beautox" are treated as implied promotion of a POM. The ASA has upheld complaints against all of these.
- Hashtags. Using #botox, #wrinklerelaxing, or related terms on social media, even in posts that do not mention the product by name.
- Before-and-after images. Where images make clear that a POM procedure was performed, they constitute implied advertising of the medicine.
- Price advertising. Publishing prices for toxin treatments implies you are promoting the service and, by extension, the POM.
The prohibition covers every channel: websites, Facebook pages, Instagram posts and stories, email newsletters, and paid digital adverts.
What Practitioners Are Allowed to Advertise
The prohibition on advertising POMs to the public does not prevent aesthetic clinics from marketing themselves. It means the focus must shift.
Permitted approaches include:
- Promoting the consultation. Advertising that you offer aesthetic consultations is allowed. The consultation itself is not a POM. Describing your qualifications, your approach, and your clinical practice is entirely within the rules.
- Advertising non-prescription treatments. Hyaluronic acid dermal fillers are currently classified as medical devices, not medicines. Skin peels, microneedling, and topical treatments are not POMs. These can be advertised, subject to the general CAP code rules on misleading claims.
- Educational and informational content. Content about how facial anatomy changes with age, how the consultation process works, or what to expect from an aesthetic appointment is not advertising a medicine. This is where clinically informed content marketing earns its keep.
- Promotion to verified healthcare professionals. Botulinum toxin can be promoted to medical, dental, veterinary, and allied health professionals. Direct professional communications remain permitted.
The practical effect for most practitioners: your public-facing website and social presence should lead with expertise, the consultation, and clinical approach. Named prescription treatments stay off public channels.
Common Compliance Failures the ASA Has Upheld
The ASA's enforcement record is instructive. Complaints have been upheld against practices for:
- Social media pages listing "Botox from £X" alongside a treatment price list
- Instagram posts showing a before-and-after image captioned with the brand name
- Facebook adverts for "wrinkle-relaxing injections," ruled an implied POM advertisement
- Training academies advertising Botox courses via public-facing social content
The JCCP, which maintains the professional register aligned with the UK's developing licensing scheme, has addressed this consistently in its guidance. Understanding and complying with CAP rules on injectable advertising is part of operating as a professional in this field, not a technicality to be managed.
The reputational risk is not abstract. ASA rulings are published publicly and indexed by search engines. A named clinic appearing in an upheld ruling carries reputational weight that takes time to undo.
Building a Compliant Marketing Presence
Compliance with POM advertising rules is not a creative constraint: it is a differentiation opportunity. Practitioners who build their marketing around clinical expertise, consultation quality, and outcomes-focused communication tend to attract clients who are not primarily price-shopping. That is a stronger long-term business position.
A compliant public-facing presence for a UK aesthetic clinic looks like this:
- Credentials and background: who the practitioner is, qualifications, clinical training
- Services described functionally: "I offer aesthetic consultations to discuss the approaches that may be appropriate for you" rather than a named treatment menu
- Educational content: information about skin ageing, the consultation process, regulatory standards
- Non-POM treatments named directly: peels, microneedling, skincare: these remain fair territory
If you are unsure whether specific content on your website or social channels breaches the rules, the ASA offers a pre-clearance service worth using before any campaign goes live.
From Regulation to Reputation is £200 off until 20 July, £299 instead of £499, with code REG299. The course is the structured programme built on Bernadette's book, Regulation to Reputation: mastering successful aesthetic practice, and the advertising compliance framework sits inside the full regulatory picture the course covers.
FAQ
Does the POM advertising ban apply to individual practitioners, or only to clinics?
It applies to any advertising of a POM to the general public, regardless of who publishes it. A sole practitioner posting about their Botox service on a personal Instagram account is subject to the same rules as a multi-site clinic. The prohibition is on the act of advertising the medicine, not the type of entity doing so.
Can I use the word "Botox" on my website at all?
The ASA considers any public-facing reference to Botox or other botulinum toxin brand names as advertising a POM. This includes references on service pages, FAQs, and blog content accessible without a login. The safe approach is to avoid naming the product on public channels entirely.
What happens if the ASA upholds a complaint against my clinic?
ASA rulings are published on the ASA's public database and indexed by search engines. You will be required to remove or amend the advertising. Repeat or serious breaches can be referred to the MHRA for formal enforcement under the Human Medicines Regulations. The reputational exposure from a published ruling is significant.
Does the ban apply to paid social advertising?
Yes. The CAP code and MHRA rules apply regardless of whether content is organic or paid. Platforms including Meta and Google also apply their own policies on advertising prescription medicines, and many ads referencing botulinum toxin products are rejected at the platform level before ASA involvement is required.
Is it legal to advertise dermal fillers?
Hyaluronic acid fillers are currently classified as medical devices in the UK, not medicines. They can be advertised, subject to the general CAP code rules on misleading claims and substantiation. Advertising filler treatments, named filler brands, or before-and-after results is currently permitted, provided claims are accurate. This position may change as the UK licensing scheme develops.